Eptifibatide CAS:188627-80-7

Eptifibatide is a drug that targets platelet function and is primarily used to treat patients with acute coronary syndromes (ACS). ACS is a disease of acute intravascular thrombosis caused by rupture of coronary plaque. Common types include unstable angina pectoris and non-ST elevation myocardial infarction. Eptifibatide reduces patients' risk of myocardial infarction or other cardiovascular events by inhibiting platelet aggregation and aggregation, preventing the formation of blood clots and further blood vessel obstruction. Clinically, Eptifibatide is often used in combination with antiplatelet drugs such as aspirin, heparin, or low molecular weight heparin to achieve a better therapeutic effect. By binding to GPIIb/IIIa receptors on the surface of platelets, it blocks the connection between fibrinogen and platelets, thereby preventing platelet aggregation and thrombosis. This drug is widely used in the treatment of acute coronary syndromes, especially for patients who require interventional cardiac therapy, such as coronary interventional surgery. In conclusion, Eptifibatide, as a potent platelet inhibitor, plays a key role in modern cardiovascular medicine, helping to reduce complications and mortality in patients with acute coronary events.